| Business Summary | | Aclara
Biosciences,
Inc.
is
a
microfluidics,
or
lab-on-a-chip,
company
with
access
to
a
wide
range
of
technology
and
intellectual
property
required
to
broadly
address
the
genomics
and
pharmaceutical
drug
screening
markets.
The
Company
is
developing
multiple
products
based
on
its
proprietary
microfluidics
technology
that
allow
researchers
to
rapidly
perform
large
numbers
of
chemical
and
biological
measurements
in
a
miniaturized,
automated
format.
In
collaboration
with
its
strategic
partners,
the
Company
is
developing
dedicated
analytical
instruments
that
will
utilize
its
LabCard
chip
products
and
assay
chemistries.
These
LabCard
systems
are
expected
to
provide
order-of-magnitude
increases
in
throughput
and
enhanced
accuracy
for
a
wide
range
of
laboratory
analyses.
The
Company
introduced
its
initial
LabCard
product,
the
Arteas
microfluidic
array
chip,
in
late
2000. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ACLA
is
a
developer
of
microfluidics,
or
lab-on-a-chip,
technology
with
access
to
technology
and
intellectual
property
required
to
address
the
markets
for
genomics,
or
RNA
and
DNA
analysis
and
pharmaceutical
drug
screening.
For
the
six
months
ended
6/30/01,
revenue
fell
less
than
1%
to
$1.8
million.
Net
loss
rose
20%
to
$13
million.
Results
reflect
a
decrease
in
collaboration
revenues
from
Applied
Biosystems
Group
and
Cellomics,
and
a
$2.4
million
litigation
settlement
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Thomas Baruch, J.D. Chairman | -- | -- | Joseph Limber, 48 Pres,
CEO, Director | $516K | $12.6M | Herbert Hooper, Ph.D., 37 Exec.
VP, CTO | 248K | 1.9M | Dennis Harris, Ph.D. Sr.
VP, R&D | -- | -- | Danny Morrow, 51 VP-Operations | 99K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|